Recruiting OBSERVATIONAL NCT06169956

An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany (NENI)

Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy for Non-Metastatic NSCLC: A German, Nationwide, Prospective, Observational, Multicenter Study in Patients Scheduled to Receive 3 Cycles Nivolumab in Combination With Platinum-Based Chemotherapy for Non-Metastatic (Stage and PD-L1 Expression According to Label) Non-Small Cell Lung Cancer

Sponsor: Bristol-Myers Squibb

Conditions Resectable Non-small Cell Lung Cancer

Interventions Neoadjuvant nivolumab in combination with platinum-based chemotherapy

Updated 5 times since 2024 Last updated: Apr 17, 2024 Started: Nov 30, 2023 Primary completion: Sep 30, 2030 Completion: Sep 30, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Resectable Non-small Cell Lung Cancer and is currently actively recruiting participants. Bristol-Myers Squibb leads this study, which shows 5 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Recruiting
Sep 2024 — Sep 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
May 2024 — Jul 2024 [monthly]

Recruiting
Jan 2024 — May 2024 [monthly]

Recruiting

First recorded

Nov 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kempten (Allgäu), Germany